FDA Approves Gene Therapy, Manufacturer Prices Drug at Record $2.8 Million

After the FDA approved Zynteglo (betibeglogene autotemcel) on Aug. 17, the gene therapy’s manufacturer, bluebird bio, Inc., announced the drug would have a $2.8 million wholesale acquisition cost (WAC). That is the highest WAC for a drug hitting the market in the U.S.

Zynteglo is indicated as a potential cure for patients with transfusion-dependent beta-thalassemia, a rare disorder caused by genetic mutations in cells that carry oxygen throughout the body. Such patients typically require red blood cell transfusions every two to five weeks.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

patient-getting-iv
August 11

Looming FDA Decisions Could Swell Number of Gene Therapies on Market

READ MORE
orphan-drugs
June 9

People With Rare Diseases Face Challenges, Require Support

READ MORE
oncology-patient-with-infusion-drug
June 9

Payers Worry About High Costs, Low Evidence for Gene Therapies

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today